Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$116.57
+5.1%
$93.43
$79.52
$124.00
$29.48B1.271.50 million shs2.96 million shs
Marriott International, Inc. stock logo
MAR
Marriott International
$356.39
-0.1%
$370.50
$256.76
$410.98
$92.93B1.11.81 million shs994,372 shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.00
+0.8%
$25.30
$23.58
$28.75
$159.99B0.3440.66 million shs37.07 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+25.22%+26.62%+26.51%+4.73%
Marriott International, Inc. stock logo
MAR
Marriott International
0.00%-0.09%-2.22%-3.46%+35.24%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+4.58%+11.90%+8.03%+10.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$116.57
+5.1%
$93.43
$79.52
$124.00
$29.48B1.271.50 million shs2.96 million shs
Marriott International, Inc. stock logo
MAR
Marriott International
$356.39
-0.1%
$370.50
$256.76
$410.98
$92.93B1.11.81 million shs994,372 shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.00
+0.8%
$25.30
$23.58
$28.75
$159.99B0.3440.66 million shs37.07 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+25.22%+26.62%+26.51%+4.73%
Marriott International, Inc. stock logo
MAR
Marriott International
0.00%-0.09%-2.22%-3.46%+35.24%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+4.58%+11.90%+8.03%+10.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.74
Moderate Buy$127.819.64% Upside
Marriott International, Inc. stock logo
MAR
Marriott International
2.60
Moderate Buy$385.658.21% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.280.99% Upside

Current Analyst Ratings Breakdown

Latest MAR, PFE, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Marriott International, Inc. stock logo
MAR
Marriott International
Lower Price TargetNeutral$412.00 ➝ $395.00
8/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeHold (C)Hold (C-)
8/12/2026
Marriott International, Inc. stock logo
MAR
Marriott International
UpgradeStrong-Buy
8/12/2026
Marriott International, Inc. stock logo
MAR
Marriott International
Initiated CoverageOutperform
8/7/2026
Marriott International, Inc. stock logo
MAR
Marriott International
Reiterated RatingBuy (B)
8/7/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetBuy$35.00 ➝ $31.00
8/5/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Set Price Target$142.00
8/5/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$130.00 ➝ $125.00
8/4/2026
Marriott International, Inc. stock logo
MAR
Marriott International
Reiterated RatingNeutral
8/4/2026
Marriott International, Inc. stock logo
MAR
Marriott International
Lower Price TargetNeutral$384.00 ➝ $374.00
8/4/2026
Marriott International, Inc. stock logo
MAR
Marriott International
Lower Price TargetOverweight$449.00 ➝ $425.00
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B9.08$1.34 per share87.31$81.64 per share1.43
Marriott International, Inc. stock logo
MAR
Marriott International
$26.19B3.55$12.45 per share28.63($17.35) per share-20.54
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.55$4.39 per share6.38$15.00 per share1.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$7.83N/AN/AN/A-63.54%-6.86%-6.00%11/3/2026 (Estimated)
Marriott International, Inc. stock logo
MAR
Marriott International
$2.60B$9.6536.9326.602.769.62%-75.81%10.56%11/3/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7636.849.56N/A6.80%19.63%8.46%11/3/2026 (Estimated)

Latest MAR, PFE, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.3983-$2.5340-$0.1357-$3.70$180.18 million$122.31 million
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
8/3/2026Q2 2026
Marriott International, Inc. stock logo
MAR
Marriott International
$3.08$3.19+$0.11$2.90$7.19 billion$2.01 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Marriott International, Inc. stock logo
MAR
Marriott International
$2.920.82%+40.63%30.26%3 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.14%-13.20%226.32%16 Years

Latest MAR, PFE, and BNTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2026
Marriott International, Inc. stock logo
MAR
Marriott International
quarterly$0.730.82%8/20/20268/20/20269/30/2026
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
7.85
7.80
Marriott International, Inc. stock logo
MAR
Marriott International
N/A
0.53
0.53
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Marriott International, Inc. stock logo
MAR
Marriott International
70.70%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Marriott International, Inc. stock logo
MAR
Marriott International
11.43%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Marriott International, Inc. stock logo
MAR
Marriott International
414,000260.77 million230.96 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Great Lakes Advisors LLC Trims Stake in Pfizer Inc. $PFE
Wealthfront Advisers LLC Reduces Position in Pfizer Inc. $PFE
Danske Bank A S Purchases 309,400 Shares of Pfizer Inc. $PFE
Pfizer’s Quiet Trial Wave Hints at Big Pipeline Upside
Prediction: This Is Where Pfizer Stock Will Be in 2030
Prediction: This Is Where Pfizer Stock Will Be in 2030
Pfizer Inc. $PFE Shares Sold by AMG National Trust Bank
Trust Co. of Vermont Makes New Investment in Pfizer Inc. $PFE
Pfizer Inc. $PFE Shares Acquired by Simplicity Wealth LLC
Pfizer Inc. $PFE Shares Sold by Trivium Point Advisory LLC
Deutsche Bank AG Buys 63,031 Shares of Pfizer Inc. $PFE
BlackRock Inc. Buys 31,412,883 Shares of Pfizer Inc. $PFE
2 Reasons to Watch PFE and 1 to Stay Cautious

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$116.57 +5.68 (+5.12%)
As of 08/21/2026 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Marriott International stock logo

Marriott International NASDAQ:MAR

$356.39 -0.21 (-0.06%)
As of 08/21/2026 04:00 PM Eastern

Marriott International, Inc. engages in operating, franchising, and licensing hotel, residential, timeshare, and other lodging properties worldwide. It operates its properties under the JW Marriott, The Ritz-Carlton, The Luxury Collection, W Hotels, St. Regis, EDITION, Bvlgari, Marriott Hotels, Sheraton, Westin, Autograph Collection, Renaissance Hotels, Le Méridien, Delta Hotels by Marriott, Tribute Portfolio, Gaylord Hotels, Design Hotels, Marriott Executive Apartments, Apartments by Marriott Bonvoy, Courtyard by Marriott, Fairfield by Marriott, Residence Inn by Marriott, SpringHill Suites by Marriott, Four Points by Sheraton, TownePlace Suites by Marriott, Aloft Hotels, AC Hotels by Marriott, Moxy Hotels, Element Hotels, Protea Hotels by Marriott, City Express by Marriott, and St. Regis Longboat Key brand names, as well as operates residences, timeshares, and yachts. The company was founded in 1927 and is headquartered in Bethesda, Maryland.

Pfizer stock logo

Pfizer NYSE:PFE

$28.00 +0.21 (+0.76%)
As of 08/21/2026 03:58 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.